SIRT2抑制剂II | 330461-64-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: SIRT2抑制剂II
• 中文别名: 3-[(六氢-1H-氮杂卓-1-基)磺酰基]-N-(3-硝基苯基)苯甲酰胺；3-[（六氢-1H-氮杂-1-基）磺酰基]-N-（3-硝基苯基）苯甲酰胺
• 英文名称: AK-1
• 英文别名: 3-(azepane-1-sulfonyl)-N-(3-nitro-phenyl)-benzamide；3-(azepan-1-ylsulfonyl)-N-(3-nitrophenyl)benzamide
• CAS: 330461-64-8
• 化学式: C₁₉H₂₁N₃O₅S
• mdl: MFCD01122550
• 分子量: 403.459
• InChiKey: HAYBKCHPEBZNGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  SIRT2抑制剂II 在 五氯化磷 、 氨 作用下， 以 苯 、 甲醇 为溶剂， 生成 3-(azepan-1-ylsulfonyl)-N-(3-nitrophenyl)benzimidamide
  参考文献：
  名称：

  [EN] BENZAMIDE COMPOUNDS AND RELATED METHODS OF USE
  [FR] COMPOSÉS BENZAMIDE ET LEURS PROCÉDÉS D'UTILISATION CONNEXES

  摘要：

  苯甲酰胺化合物及其衍生物，可用于选择性抑制SIRT2酶和/或在亨廷顿病的治疗中用于治疗用途。

  公开号：

  WO2014100833A1

文献信息

• Benzamide Compounds and Related Methods of Use
  申请人：Northwestern University

  公开号：US20150025235A1

  公开（公告）日：2015-01-22

  Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

  苯甲酰胺化合物及其衍生物可用于选择性抑制SIRT2酶和/或治疗亨廷顿病。
• COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY
  申请人：The General Hospital Corporation

  公开号：EP2068875A2

  公开（公告）日：2009-06-17
• Compositions and methods for modulating sirtuin activity
  申请人：Kazantsev Aleksey G.

  公开号：US20080021063A1

  公开（公告）日：2008-01-24

  The present invention is based, in part, on our discovery of compounds that inhibit an activity of a sirtuin (e.g., compounds that inhibit or preferentially inhibit an activity of SIRT2) and are therefore believed useful in the treatment or prevention of diseases associated with sirtuin activity. These diseases include, but are not limited to, neurological disorders such as Parkinson's Disease (PD).
• NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME
  申请人：UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.

  公开号：US20150065554A1

  公开（公告）日：2015-03-05

  Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a modulator of a target related to neurofibromatosis. Also disclosed are screening assays involving the implementation of Merlin-null Schwann cells, and to compounds identified using same.
• PHARMACEUTICAL COMPOSITION CONTAINING SIRT2 INHIBITOR
  申请人：Industrial Cooperation Foundation Chonbuk National University

  公开号：US20170128459A1

  公开（公告）日：2017-05-11

  The present invention relates to a pharmaceutical composition containing a SIRT2 inhibitor and, more specifically, to: a pharmaceutical composition for preventing or treating renal inflammatory diseases, which are caused by sepsis, by controlling inflammation-inducing factors by sepsis through the regulation of SIRT2 gene expression so as to reduce renal inflammation, thereby preventing a kidney injury; and a pharmaceutical composition for preventing or treating cancer, having an effect of increasing anticancer efficacy while reducing nephrotoxicity, which is a side effect of cisplatin, when administered together with cisplatin.